Rheumatoid Arthritis Research Today is a free monthly online journal that collates and summarizes the latest research about Rheumatoid Arthritis, including details on treatment, symptoms, causes, medication.

Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis.

van Lieshout AW, Popa C, Meyer-Wentrup F, Lemmers HL, Stalenhoef AF, Adema GJ, van Riel PL, van Tits LJ, Radstake TR

Department of Rheumatology, Radboud University Nijmegen Medical Centre and Nijmegen Centre of Molecular Life Sciences, The Netherlands.

CXCL16 acts as a scavenger receptor for oxLDL in its membrane-bound form and induces migration of activated T cells in its soluble form. Due to these properties, CXCL16 has been suggested to play a role in both atherosclerosis and rheumatoid arthritis (RA). Our aim was to evaluate the contribution of soluble CXCL16 to the scavenging of oxLDL and its potential as a marker for cardiovascular disease (CVD) in patients with RA. We found that circulating CXCL16 was not correlated with plasma oxLDL or ApoB and was not related to the presence of CVD in RA patients. Moreover, CXCL16 did not bind and scavenge oxLDL in an in vitro setting. These data suggest that binding of oxLDL by soluble CXCL16 does not play a role in atherosclerosis and, although confirmation in larger studies is needed, that circulating CXCL16 is not related to the presence of CVD in patients with RA.

Published 27 February 2007 in Biochem Biophys Res Commun, 355(2): 392-7.
Full-text of this article is available online (may require subscription).

© 2004-2008 Rheumatoid Arthritis Research Today. All Rights Reserved.